Samantha Truex's Quench Bio calls it quits after failing to solve the Gasdermin D inflammation puzzle
At the core of the biopharma industry is an experimental science. Every company and biotech out there hopes to one day prove their hypotheses and create impactful medicines that can help patients.
But science is messy, and sometimes those experiments don’t end up working as planned.
Quench Bio, the Cambridge, MA-based biotech looking for new ways to target the gene Gasdermin D in treating inflammatory diseases, has decided to wind down operations after the gene proved “undruggable” with their technology. The company announced the news in a Twitter thread Tuesday morning, and in an effort to keep Gasdermin programs moving forward, auctioned off its research.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.